Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

NCT01913691 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Merkel Cell Carcinoma

Interventions

DRUG: Ipilimumab

Sponsor

National Cancer Institute (NCI)